文献类型：期刊文献

英文题名：Amino acid metabolic reprogramming drives pathogenesis and therapy in hematologic malignancies

作者：Ren, Dexiang[1];Liu, Rong[2];Li, Wei[1];Li, Linzhou[1];Lv, Xueyin[1];Xia, Xiaojun[3];Lei, Xudong[3]

第一作者：Ren, Dexiang

通信作者：Lei, XD[1]

机构：[1]Gansu Univ Chinese Med, Sch Clin Chinese Med, Lanzhou, Peoples R China;[2]940th Hosp Joint Logist Support Force Chinese Peop, Ward 1, Comprehens Internal Med, Lanzhou, Peoples R China;[3]Gansu Prov Canc Hosp, Integrated Tradit Chinese & Western Med Oncol Dept, Lanzhou, Peoples R China

第一机构：甘肃中医药大学

通信机构：[1]corresponding author), Gansu Prov Canc Hosp, Integrated Tradit Chinese & Western Med Oncol Dept, Lanzhou, Peoples R China.

年份：2025

卷号：16

期号：1

外文期刊名：DISCOVER ONCOLOGY

收录：;Scopus(收录号：2-s2.0-105026312513);WOS:【SCI-EXPANDED(收录号:WOS:001651160600006)】；

基金：This work has been supported and funded by the Key R&D Program Project of Gansu Provincial Department of Science and Technology (No. 24YFFA019); Key Discipline Construction Project for Cultivating Talents in Traditional Chinese Medicine in Gansu Province (Gansu Provincial Department of Finance, 2022, No. 48); Gansu Province Famous Traditional Chinese Medicine Inheritance Studio Construction Project (National Traditional Chinese Medicine Finance Letter, 2021, No. 242).

语种：英文

外文关键词：Metabolic reprogramming; Hematological malignancies; Amino acid dependencies; Tumor-Immune metabolic crosstalk; Therapeutic resistance mechanisms; Targeted metabolic therapies

摘要：Hematological malignancies exhibit distinct patterns of amino acid metabolic reprogramming, which support uncontrolled proliferation, immune escape, and therapy resistance. Rather than merely fueling biosynthesis, amino acid metabolism intricately modulates tumor progression and therapeutic responses through interactions with signaling pathways such as mTOR, beta-catenin/c-Myc, and NF-kappa B. This review emphasizes the rewired utilization of key amino acids-including glutamine, arginine, leucine, tryptophan, and phenylalanine-across leukemia, lymphoma, and multiple myeloma, and discusses how these changes orchestrate immune suppression and redox imbalance. Emerging studies reveal that metabolic vulnerabilities can be therapeutically exploited via enzyme depletion, transport inhibition, or combination regimens with immunotherapies and mTOR inhibitors. Moreover, amino acid-driven drug resistance mechanisms, particularly involving stromal support and transcriptional reprogramming, pose both challenges and opportunities for next-generation treatment design. By decoding the complex metabolic-immune-tumor network, we highlight strategic interventions that leverage amino acid metabolism as a therapeutic axis in hematological cancers.